TL;DR
This study investigates a combined diagnostic approach for breast cancer, integrating dynamic enhanced MRI with three serum biomarkers (CA15-3, CYFRA21-1, and TFF1). The findings suggest that this multimodal strategy significantly improves diagnostic accuracy compared to using any single method alone, offering a promising avenue for earlier and more reliable breast cancer detection.
What Problem Does This Paper Address?
Breast cancer remains a significant global health challenge, with a high incidence and mortality rate, particularly in developing countries like China. Early detection and diagnosis are crucial for improving patient outcomes and survival rates, as they allow for timely treatment and prevent disease progression. While imaging modalities like MRI are valuable tools, their diagnostic accuracy can be influenced by factors such as radiologist experience, leading to potential missed diagnoses or misclassifications. Similarly, relying solely on individual serum biomarkers has limitations. This paper addresses the need for a more robust and accurate diagnostic strategy by exploring the synergistic potential of combining dynamic enhanced MRI with a panel of serum tumor markers (CA15-3, CYFRA21-1, and TFF1) to enhance the diagnostic efficacy for breast cancer.
Methods
The study employed a retrospective design, recruiting 180 female participants divided into three groups: 60 diagnosed with breast cancer, 60 with benign breast lesions, and 60 healthy controls. All participants underwent dynamic enhanced MRI scans. Additionally, serum levels of CA15-3 and CYFRA21-1 were measured using electrochemiluminescence, while TFF1 levels were determined via enzyme-linked immunosorbent assay (ELISA).
The MRI analysis focused on characterizing lesion boundaries, margins, and enhancement patterns, as well as analyzing time-signal intensity curves. For serological indicators, specific cutoff values were established: CA15-3 ≥ 25 U/mL, CYFRA21-1 ≥ 3.5 ng/mL, and TFF1 S/N value ≥ 2.1 were considered positive. A combined diagnosis was considered positive if any of the four modalities (MRI, CA15-3, CYFRA21-1, TFF1) yielded a positive result. Diagnostic efficacy was evaluated using sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy rate, and receiver operating characteristic (ROC) curves. Statistical analysis was performed using SPSS20.0, with t-tests and chi-square tests employed to assess differences between groups.
Datasets
The study utilized data from 180 female participants from January 2018 to December 2020, collected from a single hospital. This dataset comprised:
- 60 patients diagnosed with breast cancer (confirmed by pathological examination).
- 60 patients with benign breast lesions (confirmed by pathological examination).
- 60 healthy individuals who underwent physical examinations.
This dataset was used for both training and evaluation of the diagnostic models. No new benchmark datasets were introduced.
Key Insights and Ideas
- Synergistic Power of Multimodality: The most significant insight is that combining dynamic enhanced MRI with serum biomarkers (CA15-3, CYFRA21-1, and TFF1) offers a substantially higher diagnostic accuracy for breast cancer than any single modality alone. This highlights the value of integrating different types of diagnostic information.
- Distinct MRI Signatures: Dynamic enhanced MRI can differentiate between malignant and benign breast lesions based on specific imaging characteristics. Malignant lesions tend to exhibit obscure boundaries, irregular margins, and heterogeneous enhancement with a fast-in, fast-out time-signal intensity curve, likely due to increased vascularity. Benign lesions, conversely, show clearer boundaries, smoother margins, and often a slow-in, slow-out enhancement pattern.
- Biomarker Elevation in Cancer: Serum levels of CA15-3, CYFRA21-1, and TFF1 are significantly elevated in breast cancer patients compared to those with benign lesions or healthy controls. This suggests their utility as indicators of the presence of breast cancer.
- TFF1's Promising Role: While CA15-3 and CYFRA21-1 are established markers, TFF1 emerges as a valuable contributor to the diagnostic panel, potentially playing a role in cancer cell proliferation and apoptosis.
Key Results
- Combined Diagnosis Superiority: The combined diagnostic approach achieved a sensitivity of 95.0%, specificity of 83.3%, PPV of 74.0%, NPV of 97.1%, and an overall accuracy rate of 87.2%. The AUC for the combined diagnosis was 0.892 (95%CI = 0.840-0.943).
- Individual Modality Performance:
- CA15-3: Sensitivity 60.0%, Specificity 85.0%, Accuracy 76.7%
- CYFRA21-1: Sensitivity 56.7%, Specificity 86.7%, Accuracy 76.7%
- TFF1: Sensitivity 66.7%, Specificity 84.2%, Accuracy 78.3%
- MRI: Sensitivity 58.3%, Specificity 86.7%, Accuracy 77.2%
- Statistical Significance: The differences in serum marker levels (CA15-3, CYFRA21-1, TFF1) between the breast cancer group and the benign/control groups were statistically significant (P < 0.05).
Limitations and Future Work
Limitations: * Retrospective Design: The study's retrospective nature means it cannot establish causality and may be subject to biases inherent in reviewing past data. * Single-Center Study: Data was collected from a single hospital, which might limit the generalizability of the findings to diverse patient populations and clinical settings. * Patient Sample Size: While 180 participants were included, larger, multi-center prospective studies would provide stronger evidence. * Specific Patient Subgroups: The study notes that the sensitivity of individual markers might be related to the specific patient samples selected, suggesting potential variations in performance across different breast cancer subtypes or stages.
Future Work: * The authors conclude that combining dynamic enhanced MRI with serum CA15-3, CYFRA21-1, and TFF1 has good efficacy and can be applied in clinical diagnosis. Future research could focus on prospective validation of this combined approach in larger, multi-center cohorts. * Further investigation into the specific roles of each biomarker in different breast cancer subtypes and stages could refine the diagnostic strategy. * Exploring the integration of these markers with other emerging diagnostic technologies could lead to even more comprehensive and accurate breast cancer detection systems.
Summary updated